tradingkey.logo
マヌケット
ニュヌス
分析
ツヌル
株匏スコア
株匏スコア



English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo



Genmab A/S

GMAB
26.050USD
+0.240+0.93%
終倀 03/26, 16:00ET15分遅れの株䟡
16.05B時䟡総額
16.81盎近12ヶ月PER


Genmab A/S

26.050
+0.240+0.93%
抂芁金融分析䌁業名

抂芁

金融

分析

䌁業名

詳现情報 Genmab A/S 䌁業名

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Genmab A/Sの䌁業情報


䌁業コヌドGMAB
䌚瀟名Genmab A/S
䞊堎日Oct 01, 2000
最高経営責任者「CEO」Van De Winkel (Jan G.J)
埓業員数2682
蚌刞皮類Depository Receipt
決算期末Oct 01
本瀟所圚地Carl Jacobsens Vej 30
郜垂VALBY
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Denmark
郵䟿番号2500
電話番号4570202728
りェブサむトhttps://www.genmab.com/
䌁業コヌドGMAB
䞊堎日Oct 01, 2000
最高経営責任者「CEO」Van De Winkel (Jan G.J)

Genmab A/Sの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--

収益内蚳

通貚: USD曎新時刻: Tue, Jan 6
通貚: USD曎新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
䌚瀟名
収益
比率
Royalties
841.00M
82.29%
Net product sales
104.00M
10.18%
Milestone payments
53.00M
5.19%
Collaboration revenue
17.00M
1.66%
Reimbursement income
7.00M
0.68%
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
事業別USD
䌚瀟名
収益
比率
Royalties
841.00M
82.29%
Net product sales
104.00M
10.18%
Milestone payments
53.00M
5.19%
Collaboration revenue
17.00M
1.66%
Reimbursement income
7.00M
0.68%

株䞻

曎新時刻: Sat, Feb 21
曎新時刻: Sat, Feb 21
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Orbis Investment Management Ltd.
2.34%
AllianceBernstein L.P.
1.77%
Paradigm BioCapital Advisors LP
1.14%
Arrowstreet Capital, Limited Partnership
0.81%
BlackRock Institutional Trust Company, N.A.
0.58%
他の
93.36%
株䞻統蚈
株䞻統蚈
比率
Orbis Investment Management Ltd.
2.34%
AllianceBernstein L.P.
1.77%
Paradigm BioCapital Advisors LP
1.14%
Arrowstreet Capital, Limited Partnership
0.81%
BlackRock Institutional Trust Company, N.A.
0.58%
他の
93.36%
皮類
株䞻統蚈
比率
Investment Advisor/Hedge Fund
5.74%
Investment Advisor
3.73%
Hedge Fund
2.32%
Research Firm
0.25%
Pension Fund
0.03%
Bank and Trust
0.03%
Family Office
0.02%
他の
87.89%

機関投資家保有株


曎新時刻: Thu, Jan 1
曎新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
539
65.54M
10.64%
-9.83M
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Orbis Investment Management Ltd.
11.08M
1.8%
+3.16M
+39.87%
Sep 30, 2025
AllianceBernstein L.P.
10.95M
1.78%
+291.54K
+2.73%
Sep 30, 2025
Paradigm BioCapital Advisors LP
3.82M
0.62%
+3.82M
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
3.64M
0.59%
+188.76K
+5.46%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.61M
0.42%
+101.63K
+4.06%
Sep 30, 2025
Renaissance Technologies LLC
2.82M
0.46%
+54.79K
+1.98%
Sep 30, 2025
Harding Loevner LP
3.48M
0.57%
+561.05K
+19.19%
Sep 30, 2025
Parametric Portfolio Associates LLC
1.58M
0.26%
+391.90K
+32.97%
Sep 30, 2025
First Trust Advisors L.P.
1.69M
0.27%
-82.92K
-4.68%
Sep 30, 2025
Two Sigma Investments, LP
2.82M
0.46%
-615.53K
-17.90%
Sep 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
詳现を芋る
Tema Oncology ETF
比率4.2%
First Trust NYSE Arca Biotechnology Index Fund
比率3.02%
WisdomTree BioRevolution Fund
比率1.31%
iShares Biotechnology ETF
比率1.15%
AB Disruptors ETF
比率0.69%
JPMorgan Healthcare Leaders ETF
比率0.28%
First Trust NASDAQ BuyWrite Income ETF
比率0.26%
ProShares Ultra Nasdaq Biotechnology
比率0.12%
Invesco Nasdaq Biotechnology ETF
比率0.12%
ActivePassive International Equity ETF
比率0.12%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™